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Abstract
Background: Identification of high-risk populations for serious infection due to S. pneumoniae will permit appropriately
targeted prevention programs.
Methods: We conducted prospective, population-based surveillance for invasive pneumococcal disease and laboratory
confirmed pneumococcal pneumonia in homeless adults in Toronto, a Canadian city with a total population of 2.5 M, from
January 1, 2002 to December 31, 2006.
Results: We identified 69 cases of invasive pneumococcal disease and 27 cases of laboratory confirmed pneumococcal
pneumonia in an estimated population of 5050 homeless adults. The incidence of invasive pneumococcal disease in homeless
adults was 273 infections per 100,000 persons per year, compared to 9 per 100,000 persons per year in the general adult
population. Homeless persons with invasive pneumococcal disease were younger than other adults (median age 46 years vs
67 years, P,.001), and more likely than other adults to be smokers (95% vs. 31%, P,.001), to abuse alcohol (62% vs 15%,
P,.001), and to use intravenous drugs (42% vs 4%, P,.001). Relative to age matched controls, they were more likely to have
underlying lungdisease(12/69,17%vs17/272,6%,P=.006), butnotmorelikelytobeHIVinfected(17/69,25% vs58/282,21%,
P=.73).Theproportionofpatients withrecurrentdiseasewasfivefoldhigherforhomelessthanother adults(7/58,12% vs.24/
943, 2.5%, P,.001). In homeless adults, 28 (32%) of pneumococcal isolates were of serotypes included in the 7-valent
conjugate vaccine, 42 (48%) of serotypes included in the 13-valent conjugate vaccine, and 72 (83%) of serotypes included in
the 23-valent polysaccharide vaccine. Although no outbreaks of disease were identified in shelters, there was evidence of
clustering of serotypes suggestive of transmission of pathogenic strains within the homeless population.
Conclusions: Homeless persons are at high risk of serious pneumococcal infection. Vaccination, physical structure changes
or other program to reduce transmission in shelters, harm reduction programs to reduce rates of smoking, alcohol abuse
and infection with bloodborne pathogens, and improved treatment programs for HIV infection may all be effective in
reducing the risk.
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Introduction
Streptococcus pneumoniae is the most common cause of bacterial
pneumonia, bacteremia and meningitis in adults, and is a major
cause of morbidity and mortality in the general population [1,2].
Homeless adults may be at greater risk than other adults both
because of underlying medical conditions that increase their risk of
infection such as chronic liver disease or HIV infection [2–8], and
because communal living in shelters may be associated with
transmission of pathogenic strains [8–11]. Authors of at least two
reports of clusters of pneumococcal disease in shelters have
recommended systematic vaccination of shelter residents [9,10].
However, no national guidelines currently include such a
recommendation, and there are few data addressing the burden
of illness associated with pneumococcal infection in the homeless.
The objective of this study was to describe the epidemiology of
serious pneumococcal disease in homeless adults in metropolitan
Toronto over a five year period.
Methods
Population-based surveillance
The Toronto Invasive Bacterial Diseases Network (TIBDN) has
conducted prospective, population-based surveillance of invasive
pneumococcal disease in metropolitan Toronto, Canada (popula-
tion, 2.5 million), since 1 January 1995 [12–14]. The surveillance
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clinical care to area residents. This comprises 25 licensed
microbiology laboratories that serve 27 hospitals, long-term care
facilities and out-patient offices. Personnel from these laboratories
telephone the central TIBDN study office at the Mount Sinai
Hospital in Toronto whenever S. pneumoniae is isolated from a
sterile site or respiratory specimen. No laboratories serving this
population used urinary antigen detection for the diagnosis of
pneumococcal disease during the surveillance period. For each
case, initial demographic data and the pneumococcal isolate are
forwarded to the central TIBDN office. Additional clinical data,
including patient co-morbidities, clinical course and outcome,
antimicrobial therapy in the 3 months before presentation, and
outpatient therapy for the current episode before the blood sample
was obtained for culture, are acquired by chart review, patient
interview, and by contacting the patient’s attending physicians.
Annual audits are conducted in each laboratory to ensure
complete reporting. Surveillance and associated studies are
approved by the research ethics boards of all participating
institutions. In addition, invasive pneumococcal disease has been
reportable in Ontario since January 1, 2001, with all cases of
disease reported in Toronto investigated by Toronto Public
Health. This study included all adult (.=15 years of age) cases of
invasive pneumococcal disease and laboratory confirmed pneu-
mococcal pneumonia presenting between January 1, 2002 to
December 31, 2006, with data from TIBDN and public health
pooled to ensure accurate identification of homeless persons.
Population statistics were obtained from Statistics Canada, and
annual incidence rates calculated using the estimated population
on July 1 of each year. The population of homeless adults was
estimated to be 5052, based on a single census conducted in April,
2006 [15].
Population vaccination uptake
A publicly funded 23-valent polysaccharide vaccination pro-
gram was introduced into Ontario in 1996 [16]. The seven-valent
pneumococcal conjugate vaccine was licensed in Canada in June
2001, with a publicly funded program for infants initiated in
Ontario in January 2005 [17].
Definitions
Persons with invasive pneumococcal disease were classified as
homeless if they had no fixed address, or gave their address as an
emergency or transitional shelter. [18].
Invasive pneumococcal disease was defined as isolation of
Streptococcus pneumoniae from a sterile body fluid with a compatible
clinical syndrome. Sterile sites included blood, CSF, peritoneal
fluid, pleural fluid, or abscess aspirate, but not bronchoalveolar
lavage. Non-bacteremic pneumococcal pneumonia was defined as
per Musher et al. [19], and required: (i) a clinical presentation
including symptoms (eg. cough, sputum, fever) and physical
findings consistent with pneumonia; (ii) radiographic confirmation
of a pulmonary infiltrate; (iii) microscopic examination of a Gram
stained sputum with at least moderate numbers of white blood
cells per high power field and a predominance of Gram positive
cocci in pairs or chains; (iv) a sputum culture that yielded S.
pneumoniae but no other respiratory pathogen and (v) blood cultures
were obtained and did not yield a pathogen.
Laboratory methods
All isolates were serotyped at the central study laboratory at the
Mount Sinai Hospital, or the National Center for Streptococcus,
Edmonton, Canada using commercial antisera (Statens Serumin-
stitut, Copenhagen, Denmark). Broth microdilution antimicrobial
susceptibility testing was performed and interpreted by Clinical
and Laboratory Standards Institute standards [20].
Statistical Methods
All data was entered in duplicate and analyzed using SAS for
PC version 9.1 (SAS Institute, Cary, NC). Proportions were
compared using chi-square or Fisher’s exact tests and odds ratios
calculated with 95% confidence intervals. Two comparisons of risk
factors for invasive pneumococcal disease were conducted: one in
which risk factors in cases occurring homeless adults were
compared to all cases in other adults, and one in which cases in
homeless adults were compared a cohort of other adults
constructed by identifying, for each case in a homeless person,
the four cases of disease in housed persons closest in age.
Results
Incidence
Over the five year period, there were 69 episodes of invasive
pneumococcal disease in homeless persons, and 970 episodes in
other residents of Toronto. During the time of the study, an
estimated 5050 adults were homeless on any given day, with an
estimated 27,000 persons homeless over the course of a year.
Thus, the estimated rate of invasive disease in homeless persons
was 273 per 100,000 per year, 30 fold higher than the concurrent
rate in housed adults (9.0 per 100,000 per year). Homeless persons
comprised 6.6% of all cases of invasive pneumococcal disease, but
only 0.2% of the population of Toronto.
The typical seasonal pattern of invasive pneumococcal disease
in Toronto, with highest rates in the winter months, and a nadir in
July and August, was not present in cases in homeless persons
(Figure 1). The higher proportion of invasive disease in homeless
persons in the summer and fall could not be explained by
differences in the age, differences in the occurrence of underlying
illness or differences in the serotypes of infecting isolates (data not
shown). However, smokers who were not homeless were also more
likely to present with invasive pneumococcal disease in the
summer months: 48 of 297 (16%) cases of invasive pneumococcal
disease in smokers occurred in July and August, compared to 64 of
582 (11%,) in non-smokers, P=.03.
Figure 1. Number of cases of invasive pneumococcal disease,
by month, in homless and housed residents of Toronto, 2002–
2006. Bars represent cases in homeless persons, line represents cases in
housed persons. The proportion of infections in homeless persons was
significantly greater in summer (14/137, 10.2%) than in fall (23/305,
7.5%), winter (17/345, 4.9%) or spring (13/246, 5.3%), P=.05.
doi:10.1371/journal.pone.0007255.g001
Pneumococcus in Homeless
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7255Clinical characteristics of invasive pneumococcal disease
Characteristics of invasive pneumococcal disease in homeless
and housed adults are shown in Table 1. The most significant
difference is in age distribution: homeless adults accounted for 3%
(1/36) of cases of invasive pneumococcal disease in persons aged
,30 years of age, 19% (49/256) of cases in those aged 30–50
years, 6% (10/157) of cases in those aged 50–60 years, and 1.5%
(9/590) cases in those aged 60 years and older (P,.001). Homeless
persons were more likely than others to be smokers, to abuse
alcohol and use intravenous drugs, and to have chronic liver
disease (see Table 1). Relative to age matched controls, they were
more likely to have underlying lung disease (12/69, 17% vs 17/
272, 6%, P=.006), but not more likely to be HIV infected (17/69,
25% vs 58/282, 21%, P=.73).
Of the 69 homeless persons who presented with invasive disease,
six (9%) had received pneumococcal vaccine prior to admission.
Six additional patients were vaccinated during or shortly after
their hospitalization. Fifteen patients (22%) were known not to
have been vaccinated; data were not available (either patients did
not know their history, or they could not be contacted) for the
remaining 42 (61%) patients. Similarly, influenza vaccination
status was available for only 20 (29%) homeless patients with
invasive pneumococcal disease; 10 (50%) of these had been
vaccinated during the fall prior to their infection. In contrast, a
Table 1. Clinical characteristics of episodes of invasive pneumococcal disease in housed and homeless adults, Toronto, 2002–
2006.
Characteristic
Homeless persons
(N=69) {
All other adults
(N=970)** P value
Age matched, housed
adults (N=276)**{{ P value
Median age (range) 44.7 years (27–74 y) 66.5 years (15–108 y) ,.001 44.3 years (27–74 y) .84
Gender (N, % male) 56/69 (81%) 553/970 (57%) ,.001 183/276 (66%) .02
Underlying illness
Any* 61/69 (88%) 736/964 (76%) .09 188/275 (68%) .001
Diabetes mellitus 5/69 (7.3%) 182/950 (19%) .02 25/272 (9.2%) .81
Chronic cardiac disease 12/69 (17%) 302/950 (32%) .02 33/272 (12%) .23
Chronic lung disease 12/69 (17%) 193/950 (20%) .67 17/272 (6.2%) .006
Cancer 4/69 (5.8%) 195/950 (21%) .005 32/272 (12%) .19
Chronic liver disease 26/69 (38%) 75/950 (7.9%) ,.001 35/272 (13%) ,.001
Chronic kidney disease 2/69 (2.9%) 69/950 (7.3%) .22 11/272 (4.0%) 1.0
HIV infection 17/69 (25%) 80/950 (8.4%) ,.001 58/282 (21%) .63
Smoker 54/56 (96%) 297/963 (31%) ,.001 125/253 (49%) ,.001
Alcohol abuse 43/69 (62%) 142/950 (15%) ,.001 63/272 (23%) ,.001
Intravenous drug use 29/69 (42%) 35/950 (3.7%) ,.001 25/272 (9.2%) ,.001
Recent antibiotic exposure
Any antibiotic prior 3 mos{ 21/33 (64%) 205/762 (27%) ,.001 58/221 (26%) ,.001
Failing oral therapy1 5/63 (7.9%) 60/848 (7.1%) .80 16/245 (6.5%) .78
Clinical diagnosis
Bacteremic pneumonia 60/69 (87%) 692/949 (73%) 0.08 190/276 (69%) 0.02
Sepsis without focus 5/69 (7.2%) 140/949 (15%) 38/276 (14%)
Meningitis 2/69 (2.9%) 47/949 (5.0%) 18/276 (6.5%)
Other 2/69 (2.9%) 70/949 (7.4%) 30/276 (11%)
Required hospitalization 60/69 (87%) 838/952 (88%) .94 222/276 (80%) .54
Hospital-acquired disease 1/69 (1.4%) 49/954 (5.1%) .25 9/276 (3.5%) .69
Median length of stay (range) 6 days (1–74 days) 8 days (1–214 days) .23 6 days (1–214 days) .96
Outcome/complications
Empyema 1/69 (1.5%) 36/949 (3.8%) .51 7/276 (2.5%) 1.0
ICU admission 20/69 (29%) 273/951 (29%) .93 74/276 (27%) .39
Recurrences 7/58(12%) 24/943(2.5%) ,.001 12/276 (4.3%) .03
Death{ 10/69 (14%) 220/959 (23%) .14 37/273 (16%) .98
*Any underlying condition that would make person eligible for pneumococcal vaccination [16].
{Because of difficulty contacting homeless persons post-discharge, a much higher proportion of data is missing for homeless persons.
1Receiving antibiotics for this episode of illness when positive blood/sterile site culture obtained.
"Excluding cases with hospital-acquired disease.
{Death during hospitalization.
**Denominators vary, because not all information is available for all cases.
{{For the age-matched analysis, each homeless case was matched to the four non-homeless cases closest in age.
doi:10.1371/journal.pone.0007255.t001
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970) patients who were not homeless, and an influenza vaccination
history for 777 (80%): 28% had received pneumococcal vaccine,
and 434 (45%) had been vaccinated against influenza.
The 69 episodes of invasive disease in homeless persons
occurred in 58 patients: 6 patients had two episodes of disease,
and 1 patient had six episodes. The proportion of patients with
recurrent disease (7 of 58, 12%) was 5 fold higher than that for
housed patients during the same time period (24 of 943, 2.5%,
P,.001). One of eleven recurrent episodes may have been a
relapse: it occurred 54 days after the first episode, and the infecting
isolates were of the same serotype. All other episodes occurred
more than four months apart, and, in all cases when isolates were
available for typing, were caused by isolates of different serotypes.
Three additional patients with episodes of invasive disease while
they were homeless had another episode of disease during a time
in which they had housing. Underlying liver disease was more
common in the ten patients who had recurrent episodes of disease
than in other homeless patients (6 of 10, 60% versus 12 of 48
(25%), P=.055), but the two groups of patients did not differ in
other characteristics. The patient with six episodes of illness was a
smoker and intravenous drug user in her 50s with HIV and
hepatitis C co-infection, and known hepatic cirrhosis. The case
fatality rate was 7 of 58 (12%) for first episodes of disease in
homeless persons, compared to 3 of 7 (43%) for second episodes
(P=.06).
Of 69 episodes of invasive disease in homeless patients, 8 (12%)
were not admitted to hospital, and 7 (10%) left hospital against
medical advice. In comparison, 114 (12%) of housed patients were
not admitted to hospital, and 2 (0.2%) left against medical advice.
Clinical characteristics of laboratory-confirmed non-
bacteremic pneumococcal pneumonia
Table 2 compares the clinical characteristics of laboratory-
confirmed non-bacteremic pneumococcal pneumonia in homeless
and housed adults. As for invasive pneumococcal disease, homeless
persons were younger, less likely to be diabetic, more likely to have
chronic liver disease and HIV infection, and much more likely to
be smokers and to abuse alcohol. There were no statistically
significant differences in patient characteristics or outcomes
between homeless persons with invasive pneumococcal disease
and those with laboratory confirmed, non-bacteremic pneumo-
coccal pneumonia.
Isolate characteristics
Isolates were available for 1309 of 1383 (95%) of episodes. The
most frequently identified serotypes are shown in Table 3. Overall,
28 of 87 (32%) isolates associated with disease in homeless persons
were of serotypes included in the 7-valent conjugate vaccine, and
72 of 87 (83%) isolates were of serotypes included in the 23-valent
polysaccharide vaccine. There was no change over time in the
proportion of infections in homeless persons caused by vaccines in
Table 2. Clinical characteristics of homeless and housed adults with laboratory-confirmed non-bacteremic pneumococcal
pneumonia, Toronto, 2002–2006.
Characteristic Homeless persons (N=27) All other adults (N=317)1 P value
Median age (range) 47.4 years (26–62 yrs) 68.5 years (18–97 yrs) ,.0001
Gender (N, % male) 24/27 (89%) 208/317 (66%) .02
Underlying illness
Any* 24/27 (89%) 252/317 (80%) .31
Diabetes mellitus 0 63/317 (20%) .007
Chronic cardiac disease 5/27 (19%) 112/317 (35%) .09
Chronic lung disease 9/27 (33%) 115/317 (36%) .84
Cancer 4/27 (15%) 43/317 (14%) .77
Chronic liver disease 7/27 (26%) 20/317 (6.3%) .003
Chronic kidney disease 0 14/317 (4.4%) .61
HIV infection 4/27 (15%) 10/317 (3.2%) .02
Smoker 22/22 (100%) 108/283 (38%) ,.0001
Alcohol abuse 23/27 (85%) 57/316 (18%) ,.0001
Type of pneumonia
Treated as out-patient 3/27 (11%) 36/317 (11%) .32
Required hospitalization 21/27 (78%) 207/317 (65%)
Nosocomial 3/17 (11%) 74/317(23%)
Hospital length of stay{ (median, range) 10 days (1–169 days) 8 days (1–106 days) .42
Outcome/complications
Empyema 0 4/317 (1.3%) 1.0
ICU admission 15/27 (56%) 121/317 (38%) .12
Death{ 4/27 (15%) 43/316 (14%) .77
*Any underlying condition that would make person eligible for pneumococcal vaccination [16].
{For patients with hospitalized with community acquired disease.
{Death during hospitalization.
1Denominators vary, because not all information is available for all cases.
doi:10.1371/journal.pone.0007255.t002
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versus 9/26, 35% in 2006/7 were cause by these serotypes).
There were no differences in rates of resistance between isolates
from homeless and housed adults (data not shown). Of the 88
isolates available from episodes of illness in homeless persons: 2
(2.3%) were non-susceptible to penicillin (both with
MIC=2 mg;ml), 18 (20%) were resistant to erythromycin, 3
(3.5%) were resistant to trimethoprim-sulfamethoxazole, and 1
(1.2%) was resistant to levofloxacin.
No outbreaks of pneumonia or pneumococcal disease were
identified by either shelters or the department of public health in
Toronto during this five year period. However, there was some
evidence in our surveillance data of clustering of episodes of illness
due to particular serotypes, suggesting that transmission may have
occurred within shelters or other shared accommodation For
instance, all five episodes due to serotype 7F (6% of isolates from
homeless were of serotype 7F, compared to 2.9% among housed
cases,P=.18)occurredoveraneightmonthperiod;allthreeepisodes
due to serotype 11B (3% of isolates from homeless vs 0.7% others,
P=0.04) occurred over an eight month period. The first isolate of
serotype 12F (20% of isolates from homeless vs 4% others, P,.001),
was identified in September 2003, and all subsequent isolates
occurred inresidents of the largestshelter or those living on the street.
In addition, all ten isolates of serotype 22F identified in homeless
persons were resistant to erythromycin (MIC.=64 ug/ml); com-
pared to 14 of 79 (18%) other serotype 22F strains (P,.0001).
Discussion
Homelessness is an important and growing problem in the
developed world [19–21]. Previous studies have documented a
significant burden of illness among homeless persons due to
underlying chronic medical conditions, tuberculosis, HIV infec-
tion, trauma, and mental illnesses and addictions [18,21–25]. This
burden of chronic illness, and crowded living conditions in
shelters, would be expected to be associated with an increased
incidence of invasive pneumococcal disease. Nonetheless, the high
rates of pneumococcal disease identified in this and a previous
smaller study in Edmonton [7], are strikingly high; only patients
with AIDS, hematologic malignancies and stem cell transplants
have been identified as at similar or higher risk [14,26]. It is not
possible to distinguish from this study the extent to which the
increased incidence of disease is due to increased host susceptibility
versus increased risk of transmission of pathogenic strains in
crowded living conditions. Although most common underlying
conditions do not increase the risk of invasive pneumococcal
disease 30 fold [3–6,27,28], many homeless persons have more
than one underlying risk factor, and there are not data on risk in
persons with multiple risk factors (eg. smoking, HIV infection and
liver disease).
In keeping with the hypothesis that the host susceptibility to
invasive pneumococal disease of homeless persons is much higher
than that of other populations, we identified a five fold increased
risk of recurrent disease in this homeless population. Recurrent
invasive disease is known to be associated with serious immuno-
deficiency, in particular multiple myeloma and other malignan-
cies, HIV infections, and chronic liver disease [29–33]. Increased
host susceptibility is also likely the reason why, despite the fact that
homeless patients with invasive disease are much younger than
housed patients, their in hospital case fatality rate is almost
identical. The fact that pneumonia was more prevalent in
homeless than housed persons while bacteremia without focus
Table 3. Serotype distribution in patients with severe pneumococcal disease, Toronto, 2002–2006.
Serotype* Overall Invasive disease, Invasive disease,
Non-bacteremic
pneumonia,
Non-bacteremic
pneumonia,
N=1309 Housed N=943 Homeless N=62 Housed N=279 Homeless N=25
3{ 161 (12%) 108 (11%) 2 (3.2%) 48 (17%) 3 (12%)
14{ 112 (8.6%) 98 (10%) 3 (4.8%) 8 (2.9%) 3 (12%)
19F{ 84 (6.4%) 52 (5.5%) 0 32 (11%) 0
4{ 87 (6.7%) 73 (7.7%) 10 (16%) 2 (0.7%) 2 (8.0%)
22F{ 89 (6.8%) 63 (6.7%) 6 (9.7%) 16 (5.7%) 4 (16%)
6B{ 74 (5.7%) 54 (5.7%) 0 20 (7.1%) 0
12F{ 71 (5.4%) 51 (5.4%) 16 (26%) 3 (1.1%) 1 (4.0%)
9V{ 66 (5.0%) 51 (5.4%) 4 (6.5%) 10 (3.6%) 1 (4.0%)
6A 63 (4.8%) 41 (4.3%) 2 (3.2%) 20 (7.1%) 0
23F{ 61 (4.7%) 44 (4.7%) 1 (1.6%) 15 (5.4%) 1 (4.0%)
7F{ 41 (3.1%) 35 (3.5%) 5 (8.1%) 3 (1.1%) 0
11A{ 37 (2.8%) 21 (2.2%) 1 (1.6%) 15 (5.4%) 0
18C{ 29 (2.2%) 21 (2.2%) 1 (1.6%) 5 (1.8%) 2 (8.0%)
17F{ 12 (0.9%) 4 (0.4%) 0 6 (2.1%) 2 (8.0%)
In 7-valent conjugate vaccine 513 (39%) 393 (42%) 19 (31%) 92 (33%) 9 (36%)
In 13-valent conjugate vaccine 829 (63%) 615 (65%) 29 (46%) 172 (62%) 13 (52%)
In 23-valent polysaccharide vaccine 1042 (80%) 770 (82%) 52 (84%) 200 (72%) 20 (80%)
*Serotypes listed are those which comprise .5% of isolates from any one category of disease. During the surveillance period, there 3 episodes of invasive disease due to
serotype 1 (none in homeless persons), 10 episodes due to serotype 8 (1 in a homeless person), and no episodes of disease due to serotype 5.
{Serotypes included in 7-valent conjugate and 23 valent polysaccharide vaccine.
{Serotypes included in 23-valent polysaccharide vaccine, but not the 7-valent conjugate vaccine.
doi:10.1371/journal.pone.0007255.t003
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proportion of smokers in the homeless population predisposing to
lung infection. [5,9].
The very high proportion of smokers (95%) among homeless
persons with invasive pneumococcal disease may also explain the
fact that rates of invasive infection in homeless persons do not
decrease during the summer months in parallel to decreases in
invasive infection in other adults. If homeless persons have higher
carriage rates of S. pneumoniae [10], and the high carriage rate
persists in the summer, transmission might also explain the relative
excess of summer disease. However, one would expect crowding to
be greater in winter months when shelters are used more often.
At least four previous outbreaks of pneumococcal disease in
homeless shelters have been reported [8–11]. Disease in these
outbreaks was due to isolates of serotypes 1, 5 and/or 8, serotypes
that were rare in our population. There is some evidence in our
data that transmission of isolates of other serotypes is associated
with disease in homeless persons. We were unable to access data
regarding shelter use over time, so that it is not possible to
determine whether the apparent clustering of serotypes is due to
transmission within or outside of shelters. Further study to define
the risks for transmission of pneumococcal disease associated with
the living conditions of homeless persons is warranted.
In those patients from whom a vaccination history could be
obtained, pneumococcal vaccination rates were low. The difficulty
in obtaining vaccination histories, and the serotype distribution of
disease make vaccination programs for homeless populations a
significant challenge [34]. The coverage of 7-valent conjugate
vaccines is less than 35%, and coverage with the 13-valent
conjugate vaccine less than 50%. Although more than 80% of
disease is caused by serotypes included in the 23-valent
polysaccharide vaccine, the issue of hyporesponsiveness with
repeated doses of polysaccharide vaccine in a relatively young
population for whom consistent documentation of medical history
is clearly of concern. [35] Further, the rate of recurrent disease
suggests that this population is highly susceptible, so that vaccine
efficacy may also be compromised [36,37]. Although vaccination
was temporally associated with the termination of the two
pneumococcal outbreaks in homeless shelters in which it was used
as a control measure [10,11], important questions about the
efficacy of vaccination in this population remain.
There are a number of limitations to this study. The estimate of
incidence is based on a single census of homeless persons
conducted in April 2006; there are no standardized methods for
such a census, and no tested means of validating the number
obtained. However, the number is consistent with previous expert
estimates [15]. Further, the estimated incidence of invasive
pneumococcal disease would still be of concern even if the census
identified only 33–50% of the total homeless population. Census
data by age for homeless persons are not available, so that it is not
possible to calculate age-adjusted rates for this population. The
relatively small number of cases annually means that, although
there appeared to be no change in the serotype distribution of
disease in homeless persons in association with the introduction of
a pediatric vaccination program, our power to detect such a
difference was low. The diagnostic challenge of pneumococcal
pneumonia means that many more cases of non-bacteremic
pneumococcal pneumonia occurred than we identified; the clinical
characteristics and serotype distribution of undetected cases may
be different from those in cases identified by our surveillance.
Some data were not available for many of the cases occurring in
homeless persons – in particular, we were not able to obtain data
on prior pneumococcal vaccination in the majority of homeless
persons, and we do not have information regarding stage of disease
or treatment for those with HIV infection In addition, as noted
before, our inability to obtain data on shelter use limited the
interpretation of information regarding the potential of transmis-
sion of pneumococci in shelters.
Nonetheless, it is clear that the very high rates of invasive
pneumococcal disease, the limitations of current pneumococcal
vaccines, and the challenges of pneumococcal vaccination
program delivery in homeless populations mean that the
coordination of many different programs will be necessary to
effectively reduce the burden of pneumococcal disease in this
population. The provision of permanent housing and improved
living conditions in crowded shelters might be expected to reduce
transmission of this pathogen. Prevention and treatment programs
for alcohol, smoking and substance abuse, and programs to
improve HIV diagnosis and care delivery might prevent a fraction
of cases; similarly, increasing influenza vaccination rates might be
effective in preventing those cases secondary to influenza [38].
While all of these programs may be necessary – and all with have
benefits beyond pneumococcal disease – they are also relatively
expensive and difficult to implement. Thus, studies of the effect of
systematic or targeted pneumococcal vaccination programs
against S. pneumoniae in homeless populations, and the development
of more effective pneumococcal vaccines for adults are both
urgently needed.
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